Multiple Sklerozda Ivıg ve Plazmaferez Tedavisi

Achiron A, Pras E, Gilad R, et al. 1992. Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis. Archives of neurology 49;1233-6.

Achiron A, Rotstein Z, Noy S, Mashiach S, Dulitzky M , Achiron R. 1996. Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study. J Neurol 243;25-8.

Andersson J , Andersson U. 1990. Human intravenous immunoglobulin modulates monokine production in vitro. Immunology 71;372.

Bard F, Cannon C, Barbour R, et al. 2000. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature medicine 6;916-9.

Bieber A, Asakura K, Warrington A, Kaveri S , Rodriguez M. 2000. Antibody-mediated remyelination: relevance to multiple sclerosis. Multiple Sclerosis Journal 6;S1-S5.

Bonnan M, Valentino R, Olindo S, Mehdaoui H, Smadja D , Cabre P. 2009. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler 15;487-92.

Brück W, Bitsch A, Kolenda H, Brück Y, Stiefel M , Lassmann H. 1997. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Annals of neurology 42;783-93.

Cook S, Troiano R, Rohowsky‐Kochan C, et al. 1992. Intravenous gamma globulin in progressive MS. Acta neurologica scandinavica 86;171-5.

Dalakas MC. 1998. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology 51;S2-S8.

Dalakas MC. 1999. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine 22;1479-97.

Ehler J, Koball S, Sauer M, et al. 2015. Response to Therapeutic Plasma Exchange as a Rescue Treatment in Clinically Isolated Syndromes and Acute Worsening of Multiple Sclerosis: A Retrospective Analysis of 90 Patients. PLoS One 10;e0134583.

Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G , Mamoli B. 1997. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. The Lancet 349;589-93.

Francis GS, Freedman MS , Antel JP. 1997. Failure of intravenous immunoglobulin to arrest progression of multiple sclerosis: a clinical and MRI based study. Multiple Sclerosis Journal 3;370-6.

Frank MM, Basta M , Fries LF. 1992. The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clinical immunology and immunopathology 62;S82-S6.

Haas J. 2000. High dose IVIG in the post partum period for prevention of exacerbations in MS. Mult Scler 6 Suppl 2;S18-20; discussion S33.

Hafler D, Brod S , Weiner H. 1989. Immunoregulation in multiple sclerosis. Research in Immunology 140;233-9.

Kalanie H , Tabatabai SS. 1998. Combined immunoglobulin and azathioprine in multiple sclerosis. European neurology 39;178-81.

Kanter DS, Horensky D, Sperling RA, Kaplan JD, Malachowski ME , Churchill WH, Jr. 1995. Plasmapheresis in fulminant acute disseminated encephalomyelitis. Neurology 45;824-7.

Kaveri SV, Mouthon L , Kazatchkine MD. 1994. Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases. Journal of Neurology, Neurosurgery, and Psychiatry 57;6.

Kazatchkine MD, Bellon B , Kaveri SV. 2000. Mechanisms of action of intravenous immunoglobulin (IVIG). Multiple Sclerosis Journal 6;S24-S6.

Kazatchkine MD , Kaveri SV. 2001. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. New England Journal of Medicine 345;747-55.

Keegan M, Pineda AA, Mcclelland RL, Darby CH, Rodriguez M , Weinshenker BG. 2002. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 58;143-6.

Khatri B, Fox R, Koo A, et al. 2007. The effect of plasma exchange in accelerating clearance of natalizumab in patients with multiple sclerosis: results of the PLEX study. MULTIPLE SCLEROSIS JOURNAL. SAGE PUBLICATIONS LTD, S172-S.

Khurana DS, Melvin JJ, Kothare SV, et al. 2005. Acute disseminated encephalomyelitis in children: discordant neurologic and neuroimaging abnormalities and response to plasmapheresis. Pediatrics 116;431-6.

Lewańska M, Siger-Zajdel M , Selmaj K. 2002. No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. Eur J Neurol 9;565-72.

26.Llufriu S, Castillo J, Blanco Y, et al. 2009. Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months. Neurology 73;949-53.

Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M , Lassmann H. 2000. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society 47;707-17.

Lucchinetti C, Noseworthy J , Rodriguez M. 1997. Promotion of endogeneous remyelination in multiple sclerosis. Multiple Sclerosis Journal 3;71-5.

Lucchinetti CF, Brück W, Rodriguez M , Lassmann H. 1996. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain pathology 6;259-74.

Magaña SM, Keegan BM, Weinshenker BG, et al. 2011. Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol 68;870-8.

Miller D, Asakura K , Rodriguez M. 1995. Experimental strategies to promote central nervous system remyelination in multiple sclerosis: insights gained from the Theiler's virus model system. Journal of neuroscience research 41;291-6.

Miyamoto K , Kusunoki S. 2009. Intermittent plasmapheresis prevents recurrence in neuromyelitis optica. Ther Apher Dial 13;505-8.

Nos C, Comabella M, Tintoré M, et al. 1996. High dose intravenous immunoglobulin does not improve abnormalities in the blood-brain barrier during acute relapse of multiple sclerosis. J Neurol Neurosurg Psychiatry 61;418.

Noseworthy JH, O'brien PC, Petterson TM, et al. 2001. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 56;1514-22.

Noseworthy JH, O'brien PC, Weinshenker BG, et al. 2000. IV immunoglobulin does not reverse established weakness in MS. Neurology 55;1135-43.

Poser CM. 1997. Intravenous immunoglobulin for multiple sclerosis. Lancet 349;1177-8.

Rodriguez M , Lennon VA. 1990. Immunoglobulins promote remyelination in the central nervous system. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society 27;12-7.

Rodriguez M, Lennon VA, Benveniste EN , Merrill JE. 1987. Remyelination by oligodendrocytes stimulated by antiserum to spinal cord. Journal of Neuropathology & Experimental Neurology 46;84-95.

Ross C, Svenson M, Nielsen H, Lundsgaard C, Hansen MB , Bendtzen K. 1997. Increased in vivo antibody activity against interferon α, interleukin-1α, and interleukin-6 after high-dose Ig therapy. Blood, The Journal of the American Society of Hematology 90;2376-80.

Rothfelder U, Neu I , Pelka R. 1982. Therapy of multiple sclerosis with immunoglobulin G. MMW, Munchener Medizinische Wochenschrift 124;74-8.

Sahlas DJ, Miller SP, Guerin M, Veilleux M , Francis G. 2000. Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin. Neurology 54;1370-2.

Schuller E , Govaerts A. 1983. First results of immunotherapy with immunoglobulin G in multiple sclerosis patients. European Neurology 22;205-12.

Schuller E, Lambin P , Deloche G. 1996. Long-term treatment of multiple sclerosis with IgG immunotherapy. Pathologie-biologie 44;710-5.

Sorensen P, Wanscher B, Jensen C, et al. 1998. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 50;1273-81.

Sorensen PS. 2003. The role of intravenous immunoglobulin in the treatment of multiple sclerosis. J Neurol Sci 206;123-30.

Sorensen PS. 1996. Intravenous immunoglobulin G therapy: effects of acute and chronic treatment in multiple sclerosis. Multiple Sclerosis Journal 1;349-52.

Soukop W , Tschabitscher H. 1986. [Gamma globulin therapy in multiple sclerosis. Theoretical considerations and initial clinical experiences with 7S immunoglobulins in MS therapy]. Wien Med Wochenschr 136;477-80.

Stangel M, Boegner F, Klatt CH, Hofmeister C , Seyfert S. 2000. Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis. J Neurol Neurosurg Psychiatry 68;89-92.

Storch M , Lassmann H. 1997. Pathology and pathogenesis of demyelinating diseases. Current opinion in neurology 10;186-92.

Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P , Lassmann H. 1998. Multiple sclerosis: in situ evidence for antibody‐and complement‐mediated demyelination. Annals of neurology 43;465-71.

Strasser-Fuchs S, Fazekas F, Deisenhammer F, Nahler G, Mamoli B , Group CCOTaIIMS. 2000. The Austrian Immunoglobulin in MS (AIMS) study: final analysis. Multiple Sclerosis Journal 6;S9-S13.

Van Engelen B, Miller DJ, Pavelko KD, Hommes OR , Rodriguez M. 1994. Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 57;65-8.

Van Engelen BG, Hommes OR, Pinckers A, Cruysberg JR, Barkhof F , Rodriguez M. 1992. Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. Ann Neurol 32;834-5.

Weiner H, Dau P, Khatri B, et al. 1989. Double‐blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 39;1143-.

Weinshenker BG, O'brien PC, Petterson TM, et al. 1999. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Annals of neurology 46;878-86.

Wurster U , Haas J. 1994. Passage of intravenous immunoglobulin and interaction with the CNS. Journal of neurology, neurosurgery, and psychiatry 57;21.